West Houston Clinical Research Service

1. Moderna TX, Inc. $3,791,313 100 payments
2. GlaxoSmithKline, LLC. $617,491 37 payments
3. Seqirus USA Inc $154,941 10 payments
4. Perrigo Company plc $78,700 2 payments
5. Cipla USA Inc. $62,585 16 payments
6. Journey Medical Corporation $56,800 4 payments
7. Shionogi Inc $22,737 4 payments

1. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $1,717,040 31 payments
2. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $1,100,387 19 payments
3. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $873,953 35 payments
4. A Phase 3, Randomized, Placebo-Controlled, Observer-Blind, Multi-Count $323,023 14 payments
5. A Phase III, Randomized, Controlled, Observer-Blind Study to Evaluate $256,654 14 payments
6. A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine QIVc and a United States Licensed Quadrivalent Influenza Virus Vaccine QIV in Healthy Subjects 6 Months Through 47 Months $114,755 3 payments
7. A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus $90,933 12 payments
8. Bioequivalence study between Perrigo's product and Epiduo Forte Gel $78,700 2 payments
9. Dfd-29-Cd-004 $56,800 4 payments
10. Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects $40,186 7 payments

1. Patient care $33,100 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.